The differential effects of statins on the metastatic behaviour of prostate cancer

M. Brown, C. Hart, T. Tawadros, V. Ramani, V. Sangar, M. Lau, N. Clarke

Research output: Contribution to journalArticlepeer-review

39 Downloads (Pure)


Background: Although statins do not affect the incidence of prostate cancer (CaP), usage reduces the risk of clinical progression and mortality. Although statins are known to downregulate the mevalonate pathway, the mechanism by which statins reduce CaP progression is unknown.Methods:Bone marrow stroma (BMS) was isolated with ethical approval from consenting patients undergoing surgery for non-malignant disease. PC-3 binding, invasion and colony formation within BMS was assessed by standardised in vitro co-culture assays in the presence of different statins.Results:Statins act directly on PC-3 cells with atorvastatin, mevastatin, simvastatin (1μM) and rosuvastatin (5μM), but not pravastatin, significantly reducing invasion towards BMS by an average of 66.68% (range 53.93-77.04%; P
Original languageEnglish
Pages (from-to)1689-1696
Number of pages7
JournalBritish Journal of Cancer
Issue number10
Publication statusPublished - 8 May 2012


  • Bone marrow stroma
  • Metastasis
  • Prostate cancer
  • Statins

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre


Dive into the research topics of 'The differential effects of statins on the metastatic behaviour of prostate cancer'. Together they form a unique fingerprint.

Cite this